Mohammed Alhashemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Alhashemi has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Amine Ghram
Cardiac Rehabilitation, Hamad Medical Corporation, Doha, Doha, 3050
3 shared publications - Javier Loureiro Diaz
Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, 3050, Qatar; Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of Coruña, Oleiros, Coruña, Spain
3 shared publications Omar Ibrahim
Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, 3050, Doha, Qatar
3 shared publications- Praveen Jayaprabha Surendran
Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, 3050, Doha, Qatar
3 shared publications - Prasobh Jacob
Prasobh Jacob, MSc, ACSM-CEP, AACVPR-CCRP, Physiotherapy Specialist, Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
2 shared publications - Rajvir Singh
Department of Cardiology, Hamad Medical Corporation, Doha, Qatar
2 shared publications
Latest Publications
- 15 June 2026
- Published by Springer Nature in Sports Medicine
- Vol. 56 (10) , 2413-2434
Toward Precision Cardiac Rehabilitation: Current Limitations and Future Opportunities of Omics and Artificial Intelligence
Cardiovascular disease involves complex molecular, cellular, and physiological derangements that present challenges for traditional diagnostic and therapeutic approaches. Precision medicine is an evolving field that seeks to tailor interventions according to an individual's genetic, molecular, and physiological characteristics. By leveraging advanced omics approaches, including genomics, proteomics, metabolomics, and microbiomics, precision medicine may enable more comprehensive patient phenotyping and support the development of more individualized strategies. The emerging concept of precision cardiac rehabilitation (CR) could provide a more tailored approach to cardiac care by integrating artificial intelligence (AI) with multimodal data, including clinical, imaging, physiological, and omics information. In this context, AI has been explored as a tool to support risk assessment, exercise prescription, and monitoring during CR. However, current evidence remains limited and heterogeneous. Omics-based approaches are primarily confined to research and translational settings, and their role in guiding individualized exercise prescription or clinical decision making in CR remains unestablished. Similarly, while AI shows promise for improving adherence, remote monitoring, and data integration, its effectiveness for optimizing clinical outcomes in CR requires further validation. Overall, precision CR represents a promising but still evolving paradigm. Future progress will depend on well-designed clinical trials, real-world data integration, standardized methodologies, and interdisciplinary collaboration to determine whether these technologies can be safely and effectively integrated into routine clinical practice.
- 15 June 2026
- Published by Springer Nature in Sports Medicine
- Vol. 56 (10) , 2413-2434
Toward Precision Cardiac Rehabilitation: Current Limitations and Future Opportunities of Omics and Artificial Intelligence
Cardiovascular disease involves complex molecular, cellular, and physiological derangements that present challenges for traditional diagnostic and therapeutic approaches. Precision medicine is an evolving field that seeks to tailor interventions according to an individual's genetic, molecular, and physiological characteristics. By leveraging advanced omics approaches, including genomics, proteomics, metabolomics, and microbiomics, precision medicine may enable more comprehensive patient phenotyping and support the development of more individualized strategies. The emerging concept of precision cardiac rehabilitation (CR) could provide a more tailored approach to cardiac care by integrating artificial intelligence (AI) with multimodal data, including clinical, imaging, physiological, and omics information. In this context, AI has been explored as a tool to support risk assessment, exercise prescription, and monitoring during CR. However, current evidence remains limited and heterogeneous. Omics-based approaches are primarily confined to research and translational settings, and their role in guiding individualized exercise prescription or clinical decision making in CR remains unestablished. Similarly, while AI shows promise for improving adherence, remote monitoring, and data integration, its effectiveness for optimizing clinical outcomes in CR requires further validation. Overall, precision CR represents a promising but still evolving paradigm. Future progress will depend on well-designed clinical trials, real-world data integration, standardized methodologies, and interdisciplinary collaboration to determine whether these technologies can be safely and effectively integrated into routine clinical practice.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 41 (5) , 422-433
Silent Myocardial Ischemia: Safety and Effectiveness of Exercise-Based Cardiac Rehabilitation
Background: Silent myocardial ischemia (SMI) predicts adverse outcomes in coronary artery disease, yet the effects of cardiac rehabilitation (CR) in this group are limited. We evaluated the impact of CR on peak exercise capacity, ischemic threshold, training workload progression, medication adherence, depression, and exercise-related adverse events in patients with documented SMI Type I and II. Methods: This retrospective cohort study includes 966 patients referred to CR. Twenty-nine patients who completed ≥1 session and had valid pre and post exercise tests were included in the final analysis. Main outcomes were changes in peak exercise capacity and ischemic threshold. Rate of adverse events, medication compliance, adverse drug reactions, and cardiac depression scores were also evaluated. Paired t tests were used (α=0.05). Results: Exercise-based CR resulted in a clinically and statistically significant improvement in exercise capacity (MET peak : 8.43 ± 2.51 to 9.14 ± 2.81, P < .001). At ischemic threshold, heart rate increased (123.94 ± 16.08 to 127.82 ± 17.23, P < .001), systolic blood pressure reduced (167.41 ± 33.14 to 164.41 ± 22.59, P = .006), and rate-pressure product increased (21939.53 ± 5362.54 to 22013.88 ± 4203.48, P = .009). The rate of exercise-related adverse events was low (2.23 per 100 sessions), with no major adverse events. Compliance with medications remained above 85% pre-to-post CR, with only 1 reported adverse drug reaction. Conclusions: Exercise-based CR is safe and effective for patients with SMI, improving exercise capacity and ischemic tolerance with few adverse events. These findings support integrating CR into the management of asymptomatic, high-risk coronary patients.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 41 (5) , 422-433
Silent Myocardial Ischemia: Safety and Effectiveness of Exercise-Based Cardiac Rehabilitation
Background: Silent myocardial ischemia (SMI) predicts adverse outcomes in coronary artery disease, yet the effects of cardiac rehabilitation (CR) in this group are limited. We evaluated the impact of CR on peak exercise capacity, ischemic threshold, training workload progression, medication adherence, depression, and exercise-related adverse events in patients with documented SMI Type I and II. Methods: This retrospective cohort study includes 966 patients referred to CR. Twenty-nine patients who completed ≥1 session and had valid pre and post exercise tests were included in the final analysis. Main outcomes were changes in peak exercise capacity and ischemic threshold. Rate of adverse events, medication compliance, adverse drug reactions, and cardiac depression scores were also evaluated. Paired t tests were used (α=0.05). Results: Exercise-based CR resulted in a clinically and statistically significant improvement in exercise capacity (MET peak : 8.43 ± 2.51 to 9.14 ± 2.81, P < .001). At ischemic threshold, heart rate increased (123.94 ± 16.08 to 127.82 ± 17.23, P < .001), systolic blood pressure reduced (167.41 ± 33.14 to 164.41 ± 22.59, P = .006), and rate-pressure product increased (21939.53 ± 5362.54 to 22013.88 ± 4203.48, P = .009). The rate of exercise-related adverse events was low (2.23 per 100 sessions), with no major adverse events. Compliance with medications remained above 85% pre-to-post CR, with only 1 reported adverse drug reaction. Conclusions: Exercise-based CR is safe and effective for patients with SMI, improving exercise capacity and ischemic tolerance with few adverse events. These findings support integrating CR into the management of asymptomatic, high-risk coronary patients.
- Open Access
- 24 September 2024
- Published by Taylor & Francis in Libyan Journal of Medicine
- Vol. 19 (1) , 2406110
Impact of cardiac rehabilitation exercise frequency on exercise capacity in patients with coronary artery disease: a retrospective study
Cardiac rehabilitation (CR) significantly improves cardiovascular outcomes in patients with coronary artery disease (CAD). International guidelines vary in the minimum recommended frequency of supervised exercise from 1 to 3 sessions per week. This is the first study in the Middle East and North African regions assessing the impact of 2 versus 3 days/week of supervised exercise on peak exercise capacity in patients with CAD. Single-center retrospective cohort study involving 362 patients enrolled in the only CR center in the State of Qatar. Only high-quality data was included by strict evaluation of compliance to the exercise intervention. Fifty patients who underwent a symptom-limited exercise test before and after CR were included (31 patients on 2 days/week, 19 on 3 days/week). No significant differences were observed in baseline characteristics between groups. Exercise intervention differed significantly between groups in exercise training frequency (2 days/week: 1.97 ± 0.2 vs. 3 days/week: 2.7 ± 0.3; p < 0.00). Peak exercise capacity as peak metabolic equivalents of task (MET) significantly increased in both groups (2 days/week: Pre 8.3 ± 2.4 vs. Post 9.4 ± 2.9, p-value 0.00; 3 days/week: Pre 7.4 ± 1.6 vs. Post 8.4 ± 2.0, p-value 0.00). No significant difference was observed between groups for change in Peak Exercise Capacity (2 days/week 1.1 ± 1.1 vs. 3 days/week 1.0 ± 0.9, p = 0.87). When the total number of exercise sessions is equal, supervised exercise frequencies of 2 and 3 days/week may significantly and equally improve peak exercise capacity in patients with CAD.
- 24 September 2024
- Published by Taylor & Francis in Libyan Journal of Medicine
- Vol. 19 (1) , 2406110
Open AccessImpact of cardiac rehabilitation exercise frequency on exercise capacity in patients with coronary artery disease: a retrospective study
Cardiac rehabilitation (CR) significantly improves cardiovascular outcomes in patients with coronary artery disease (CAD). International guidelines vary in the minimum recommended frequency of supervised exercise from 1 to 3 sessions per week. This is the first study in the Middle East and North African regions assessing the impact of 2 versus 3 days/week of supervised exercise on peak exercise capacity in patients with CAD. Single-center retrospective cohort study involving 362 patients enrolled in the only CR center in the State of Qatar. Only high-quality data was included by strict evaluation of compliance to the exercise intervention. Fifty patients who underwent a symptom-limited exercise test before and after CR were included (31 patients on 2 days/week, 19 on 3 days/week). No significant differences were observed in baseline characteristics between groups. Exercise intervention differed significantly between groups in exercise training frequency (2 days/week: 1.97 ± 0.2 vs. 3 days/week: 2.7 ± 0.3; p < 0.00). Peak exercise capacity as peak metabolic equivalents of task (MET) significantly increased in both groups (2 days/week: Pre 8.3 ± 2.4 vs. Post 9.4 ± 2.9, p-value 0.00; 3 days/week: Pre 7.4 ± 1.6 vs. Post 8.4 ± 2.0, p-value 0.00). No significant difference was observed between groups for change in Peak Exercise Capacity (2 days/week 1.1 ± 1.1 vs. 3 days/week 1.0 ± 0.9, p = 0.87). When the total number of exercise sessions is equal, supervised exercise frequencies of 2 and 3 days/week may significantly and equally improve peak exercise capacity in patients with CAD.